32
styled-text
Expect RAS
margin-top-none
margin-bottom-md
mobile-margin-top-none
mobile-margin-bottom-10
text-color-purple
styled-text
RAS drives cancer in ~1 in 3 patients1
font-mobile-size-26
margin-bottom-md
mobile-margin-bottom-10
text-color-brown-533405
font-family-roboto
fit
true
m
top
start
false
Explore RAS in
Explore RAS in PDAC- link to learn more, shown next to an illustration of a yellow pancreas entwined with a vine that spells out RAS.
Explore RAS in
Explore RAS in NSCLC- link to learn more, shown next to an illustration of lungs formed from flower petals entwined with vines that are etched with G12D, G12C, G12V, and G12A.
styled-text
NSCLC=non-small cell lung cancer; PDAC=pancreatic ductal adenocarcinoma; RAS=rat sarcoma.
margin-top-md
margin-bottom-xs
text-color-brown-533405
font-family-inter
styled-text
Reference: 1. Lokhandwala J, Smalley TB, Tran TH. Structural perspectives on recent breakthrough efforts toward direct drugging of RAS and acquired resistance. Front Oncol. 2024;14:1394702. doi:10.3389/fonc.2024.1394702
text-color-brown-533405
font-family-inter
64
mobile-30
64
mobile-30